The addition of a CDK4/6 inhibitor to endocrine therapy prolonged progression-free survival (PFS) and overall survival (OS) in patients with advanced or metastatic HR+/HER2– breast cancer [8,9,10,11]. The gene discussed is ERBB2; the disease is breast cancer.